{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:21:59Z","timestamp":1774952519121,"version":"3.50.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"vor","delay-in-days":387,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.vaccine.2023.02.031","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T21:43:27Z","timestamp":1677015807000},"page":"2127-2136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety and immunogenicity of the anti-cocaine vaccine UFMG-VAC-V4N2 in a non-human primate model"],"prefix":"10.1016","volume":"41","author":[{"given":"Brian","family":"Sabato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo S\u00e9rgio de Almeida","family":"Augusto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raissa","family":"Lima Gon\u00e7alves Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Coutinho Batista Esteves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sordaini M.","family":"Caligiorne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruna","family":"Rodrigues Dias Assis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f3stenes","family":"Apolo Correia Marcelino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larissa","family":"Pires do Esp\u00edrito Santo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Dias dos Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Da Silva Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisele","family":"Goulart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c2ngelo","family":"de F\u00e1tima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Pierezan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Toshio Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maila","family":"Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1926-9053","authenticated-orcid":false,"given":"Frederico","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.02.031_b0005","article-title":"The Growing Epidemic of Opioid Use Disorder in the Elderly and Its Treatment: A Review of the Literature","volume":"25","author":"Konakanchi","year":"2023","journal-title":"Prim Care Companion CNS Disord"},{"key":"10.1016\/j.vaccine.2023.02.031_b0010","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1002\/hep4.2080","article-title":"Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease","volume":"6","author":"Ayyala","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.vaccine.2023.02.031_b0015","doi-asserted-by":"crossref","DOI":"10.1111\/add.16126","article-title":"An intensive longitudinal examination of topiramate treatment for alcohol use disorder: a secondary analysis of data from a randomized controlled trial","author":"Votaw","year":"2023","journal-title":"Addiction"},{"key":"10.1016\/j.vaccine.2023.02.031_b0020","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0376-8716(97)00121-X","article-title":"Development of a therapeutic vaccine for the treatment of cocaine addiction","volume":"48","author":"Fox","year":"1997","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.vaccine.2023.02.031_b0025","doi-asserted-by":"crossref","first-page":"6202","DOI":"10.1073\/pnas.97.11.6202","article-title":"Cocaine vaccines: antibody protection against relapse in a rat model","volume":"97","author":"Carrera","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2023.02.031_b0030","first-page":"139","article-title":"Antibodies against small molecules","volume":"27","author":"Clementi","year":"1991","journal-title":"Ann Ist Super Sanita"},{"key":"10.1016\/j.vaccine.2023.02.031_b0035","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1073\/pnas.042700599","article-title":"Covalent modification of proteins by cocaine","volume":"99","author":"Deng","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2023.02.031_b0040","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1021\/acsmedchemlett.8b00051","article-title":"Efficient Syntheses of Cocaine Vaccines and Their in Vivo Evaluation","volume":"9","author":"Kimishima","year":"2018","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.vaccine.2023.02.031_b0045","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1517\/14712598.2014.920319","article-title":"The future potential for cocaine vaccines","volume":"14","author":"Orson","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2023.02.031_b0050","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41541-020-0161-1","article-title":"Novel mucosal adjuvant, mastoparan-7, improves cocaine vaccine efficacy","volume":"5","author":"St John","year":"2020","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2023.02.031_b0055","article-title":"Low doses of pharmaceutical formulations loaded with UFMG-V4N2 immunogen induce the production of IgG anti-cocaine antibodies and provide evidence of cerebral protection in preclinical model","author":"Assis, B.R.D.","year":"2023","journal-title":"JCIS Open"},{"key":"10.1016\/j.vaccine.2023.02.031_b0060","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jare.2021.09.003","article-title":"Calix[n]arene-based immunogens: A new non-proteic strategy for anti-cocaine vaccine","volume":"38","author":"da Silva Neto","year":"2022","journal-title":"J Adv Res"},{"key":"10.1016\/j.vaccine.2023.02.031_b0065","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1002\/1521-4141(200112)31:12<3816::AID-IMMU3816>3.0.CO;2-K","article-title":"Rationally designed strings of promiscuous CD4(+) T cell epitopes provide help to Haemophilus influenzae type b oligosaccharide: a model for new conjugate vaccines","volume":"31","author":"Falugi","year":"2001","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2023.02.031_b0070","article-title":"ANTI-COCAINE VACCINE","volume":"6,383,490 B1","author":"Peter Wirsching","year":"2002","journal-title":"United States patent"},{"key":"10.1016\/j.vaccine.2023.02.031_b0075","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/378727a0","article-title":"Suppression of psychoactive effects of cocaine by active immunization","volume":"378","author":"Carrera","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.02.031_b0080","doi-asserted-by":"crossref","unstructured":"Rosenberg, J. B. et al. AAVrh.10-Mediated Expression of an Anti-Cocaine Antibody Mediates Persistent Passive Immunization That Suppresses Cocaine-Induced Behavior. Human gene therapy 23, 451-459 (2012). 10.1089\/hum.2011.178.","DOI":"10.1089\/hum.2011.178"},{"key":"10.1016\/j.vaccine.2023.02.031_b0085","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1021\/mp200588v","article-title":"An antidote for acute cocaine toxicity","volume":"9","author":"Treweek","year":"2012","journal-title":"Mol Pharm"},{"key":"10.1016\/j.vaccine.2023.02.031_b0090","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/npp.2011.200","article-title":"Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects","volume":"37","author":"Wee","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.vaccine.2023.02.031_b0095","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0264-410X(01)00425-X","article-title":"Human therapeutic cocaine vaccine: safety and immunogenicity","volume":"20","author":"Kosten","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.02.031_b0100","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.biopsych.2005.04.032","article-title":"Vaccine pharmacotherapy for the treatment of cocaine dependence","volume":"58","author":"Martell","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.vaccine.2023.02.031_b0105","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1001\/archgenpsychiatry.2009.128","article-title":"Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial","volume":"66","author":"Martell","year":"2009","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.vaccine.2023.02.031_b0110","unstructured":"Clinicaltrials.gov. Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals, <https:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT02455479?term=vaccine&cond=Cocaine+Dependence&draw=2&rank=2> (2015)."},{"key":"10.1016\/j.vaccine.2023.02.031_b0115","series-title":"in MA\/CPMP\/ICH\/286\/1995 (ed Science Medicines Health)","author":"European Medicines Agency","year":"2009"},{"key":"10.1016\/j.vaccine.2023.02.031_b0120","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.vascn.2012.01.002","article-title":"Overview of global regulatory toxicology requirements for vaccines and adjuvants","volume":"65","author":"Sun","year":"2012","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.vaccine.2023.02.031_b0125","unstructured":"World Health Organization (WHO). WHO guidelines on nonclinical evaluation of vaccines. WHO Technical Report Series 927 (2003)."},{"key":"10.1016\/j.vaccine.2023.02.031_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vascn.2012.04.003","article-title":"Study designs for the nonclinical safety testing of new vaccine products","volume":"66","author":"Forster","year":"2012","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.vaccine.2023.02.031_b0135","series-title":"in EMEA\/CHMP\/VEG\/134716\/2004 (eds COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE & (CHMP))","author":"European Medicines Agency","year":"2005"},{"key":"10.1016\/j.vaccine.2023.02.031_b0140","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1016\/0040-4039(96)01170-7","article-title":"Design and synthesis of a cocaine-diamide hapten for vaccine development","volume":"37","author":"Sakurai","year":"1996","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.vaccine.2023.02.031_b0145","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1021\/mp400214w","article-title":"Probing the effects of hapten stability on cocaine vaccine immunogenicity","volume":"10","author":"Cai","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1016\/j.vaccine.2023.02.031_b0150","unstructured":"F\u00e1tima, A. d. et al. Molecules that stimulate the immune system for treatment of drug addiction, methods of synthesis, antidrug vaccine drug use. United States patent (2020)."},{"key":"10.1016\/j.vaccine.2023.02.031_b0155","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1021\/jm400228w","article-title":"Probing active cocaine vaccination performance through catalytic and noncatalytic hapten design","volume":"56","author":"Cai","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.vaccine.2023.02.031_b0160","series-title":"Compara\u00e7\u00e3o de t\u00e9cnicas de ensaio de absor\u00e7\u00e3o imuno-enzim\u00e1tico (ELISA)para avalia\u00e7\u00e3o da reatividade de anticorpos anti-coca\u00edna tipo IgG em. camundongos","author":"Pereira","year":"2019"},{"key":"10.1016\/j.vaccine.2023.02.031_b0165","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1258\/002367778780953215","article-title":"Circadian oscillations of body temperature in the marmoset","volume":"12","author":"Hetherington","year":"1978","journal-title":"Callithrix jacchus Lab Anim"},{"key":"10.1016\/j.vaccine.2023.02.031_b0170","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1600-0684.2005.00101.x","article-title":"Comparison between sex and age class on some physiological, thermal, and hematological indices of the cerrado's marmoset (Callithrix penicillata)","volume":"34","author":"Boere","year":"2005","journal-title":"J Med Primatol"},{"key":"10.1016\/j.vaccine.2023.02.031_b0175","unstructured":"Melbourne Vaccine Education Centre. Adversing events reporting Australia, <https:\/\/mvec.mcri.edu.au\/references\/adverse-events-reporting-australia\/> (."},{"key":"10.1016\/j.vaccine.2023.02.031_b0180","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/jat.3314","article-title":"Dose site reactions and related findings after vaccine administration in safety studies","volume":"36","author":"Baldrick","year":"2016","journal-title":"J Appl Toxicol"},{"key":"10.1016\/j.vaccine.2023.02.031_b0185","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10329-016-0520-8","article-title":"Clinical, hematological, biochemical, and ultrasonographic aspects of Platynosomum sp. (Trematoda: Dicrocoeliidae) infection of captive Callithrix penicillata","volume":"57","author":"Mattioli","year":"2016","journal-title":"Primates"},{"key":"10.1016\/j.vaccine.2023.02.031_b0190","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1177\/0300985811427151","article-title":"Spontaneous glomerular and tubulointerstitial lesions in common marmosets (Callithrix jacchus)","volume":"49","author":"Isobe","year":"2012","journal-title":"Vet Pathol"},{"key":"10.1016\/j.vaccine.2023.02.031_b0195","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1177\/0192623313478206","article-title":"Morphological study of progressive glomerulonephropathy in common marmosets (Callithrix jacchus)","volume":"41","author":"Yamada","year":"2013","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.vaccine.2023.02.031_b0200","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1016\/j.vaccine.2013.07.038","article-title":"Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food","volume":"31","author":"Ruedi-Bettschen","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.02.031_b0205","doi-asserted-by":"crossref","first-page":"e0239780","DOI":"10.1371\/journal.pone.0239780","article-title":"Cocaine vaccine dAd5GNE protects against moderate daily and high-dose \u201cbinge\u201d cocaine use","volume":"15","author":"Havlicek","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.02.031_b0210","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.clpt.2005.08.007","article-title":"Safety and immunogenicity of a nicotine conjugate vaccine in current smokers","volume":"78","author":"Hatsukami","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.vaccine.2023.02.031_b0215","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/eji.200526285","article-title":"A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity","volume":"35","author":"Maurer","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2023.02.031_b0220","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1186\/1471-2458-12-1052","article-title":"The efficacy and safety of a nicotine conjugate vaccine (NicVAX(R)) or placebo co-administered with varenicline (Champix(R)) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo controlled trial","volume":"12","author":"Hoogsteder","year":"2012","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2023.02.031_b0225","doi-asserted-by":"crossref","first-page":"e1001291","DOI":"10.1371\/journal.pbio.1001291","article-title":"Research chimpanzees may get a break","volume":"10","author":"de Waal","year":"2012","journal-title":"PLoS Biol"},{"key":"10.1016\/j.vaccine.2023.02.031_b0230","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.coviro.2012.02.007","article-title":"An animal model that reflects human disease: the common marmoset (Callithrix jacchus)","volume":"2","author":"Carrion","year":"2012","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2023.02.031_b0235","doi-asserted-by":"crossref","first-page":"667","DOI":"10.4161\/hv.7.6.14981","article-title":"Vaccines against viral hemorrhagic fevers: non-human primate models","volume":"7","author":"Carrion","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2023.02.031_b0240","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1099\/vir.0.031229-0","article-title":"Common marmoset (Callithrix jacchus) as a primate model of dengue virus infection: development of high levels of viraemia and demonstration of protective immunity","volume":"92","author":"Omatsu","year":"2011","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2023.02.031_b0245","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5731\/pdajpst.2011.00634","article-title":"Excipients and their role in approved injectable products: current usage and future directions","volume":"65","author":"Nema","year":"2011","journal-title":"PDA J Pharm Sci Technol"},{"key":"10.1016\/j.vaccine.2023.02.031_b0250","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1080\/03639045.2018.1483392","article-title":"Excipients in parenteral formulations: selection considerations and effective utilization with small molecules and biologics","volume":"44","author":"Rayaprolu","year":"2018","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.vaccine.2023.02.031_b0255","unstructured":"FDA. <https:\/\/www.accessdata.fda.gov\/scripts\/cder\/iig\/index.cfm?event=browseByLetter.page&Letter=P> (."},{"key":"10.1016\/j.vaccine.2023.02.031_b0260","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jaip.2018.12.003","article-title":"Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized","volume":"7","author":"Stone","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.vaccine.2023.02.031_b0265","unstructured":"Institute for Vaccine Safety. Excipients in Vaccine per 0.5ml dose., <https:\/\/vaccinesafety.edu\/components-excipients.htm> (."},{"key":"10.1016\/j.vaccine.2023.02.031_b0270","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1023\/B:PHAM.0000016235.32639.23","article-title":"Solubilizing excipients in oral and injectable formulations","volume":"21","author":"Strickley","year":"2004","journal-title":"Pharm Res"},{"key":"10.1016\/j.vaccine.2023.02.031_b0275","unstructured":"Agency, E. M. <https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/covid-19-vaccine-janssen-epar-product-information_en.pdf> (2021)."},{"key":"10.1016\/j.vaccine.2023.02.031_b0280","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.jaip.2020.12.047","article-title":"mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach","volume":"9","author":"Banerji","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.vaccine.2023.02.031_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2021.100517","article-title":"COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee","volume":"14","author":"Turner","year":"2021","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.vaccine.2023.02.031_b0290","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.0818-9641.2004.01286.x","article-title":"Aluminium compounds for use in vaccines","volume":"82","author":"Lindblad","year":"2004","journal-title":"Immunol Cell Biol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23001664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23001664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:23:51Z","timestamp":1759404231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23001664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":58,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0264410X23001664"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.02.031","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of the anti-cocaine vaccine UFMG-VAC-V4N2 in a non-human primate model","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.02.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}